Test Price
2,800 AED✅ Home Collection Available
GSN Gene Finnish Type Amyloidosis Genetic Test in UAE | 2800 AED | DHA-Licensed Genomics
Executive Summary & Core Metrics
Executive Summary – UAE Precision Genomics
- Diagnostic Accuracy: 99.9% analytical sensitivity for single nucleotide variants and small indels via NGS in an ISO 9001:2015 accredited laboratory (Certificate INT/EGQ/2509DA/3139).
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM across Dubai, Abu Dhabi, and Sharjah.
- Post-Test Counselling: Telephonic result interpretation session with a DHA-licensed Consultant Medical Genetics following report release.
- Insurance Support: Direct billing verification and pre-authorisation assistance via WhatsApp +971 54 548 8731.
Guaranteed cold-chain home collection (8 AM – 11 PM) | 3–4 Week TAT | DHA-licensed facility (License No. 1143) | Direct Billing Support
Test Overview & Methodology
The GSN gene (gelsolin) Finnish type amyloidosis test employs high-sensitivity next-generation sequencing to detect disease-causing mutations in the gelsolin gene associated with hereditary gelsolin amyloidosis (Meretoja disease). This assay is indicated for symptomatic patients presenting with progressive cranial neuropathy, corneal lattice dystrophy, and cutis laxa, as well as for at-risk family members seeking predictive testing. The analysis covers more than 99 percent of the coding region with variant interpretation performed according to ACMG guidelines.
| Parameter | Our GSN NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Analytical Sensitivity | >99.9% for single nucleotide variants and small indels | ~99.0%; may miss larger deletions or mosaicism |
| Methodology | NGS – full gene coverage with high-depth sequencing | Sanger sequencing; lower throughput, single-exon focus |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
Physician Insight & Safety Protocols
"As a DHA-licensed Consultant Medical Genetics, I emphasise that a positive GSN gene test confirms a predisposition to hereditary gelsolin amyloidosis but must be interpreted within the complete clinical picture including neurological examination, corneal assessment, and three-generation family history. This molecular tool enables early therapeutic intervention and informed family counselling, yet it remains one integral component of a comprehensive diagnostic evaluation." — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory – Medication Safety
⚠️ Important Medication Guidance
Do not discontinue, adjust, or initiate any prescribed medication without direct consultation with your treating physician. This genetic test result does not replace ongoing clinical follow-up or specialist evaluation by a neurologist or geneticist.
Exclusion Criteria & Sample Requirements
Safety Triage & Logistics
- Exclusion Criteria: Active febrile illness or acute phase of a chronic disease that may interfere with sample collection; patient must be haemodynamically stable for home phlebotomy.
- Emergency Red Flags: If you experience sudden severe facial weakness, acute vision loss, unremitting dizziness, or an acute confusional state, proceed to the nearest emergency department immediately – do not wait for test results.
- Sample Requirements: Whole blood (EDTA tube), extracted DNA, or dried blood spot on FTA card. A clinical history and a pre-test genetic counselling session with pedigree charting are mandatory before sample collection.
Patient FAQ & Clinical Guidance
1. What exactly does the GSN Finnish type amyloidosis NGS test detect?
The test identifies disease-causing mutations in the gelsolin (GSN) gene that lead to hereditary gelsolin amyloidosis, a progressive neurological syndrome also known as Meretoja disease. It analyses more than 99 percent of the coding region using next-generation sequencing with variant interpretation performed according to ACMG guidelines. The assay can detect single nucleotide variants, small insertions and deletions, and splice-site alterations.
2. How is the test performed and what is the turnaround time?
A small blood sample, extracted DNA, or a dried blood spot on an FTA card is collected via hospital-grade home phlebotomy by our trained nursing team under temperature-controlled cold-chain conditions. Sequencing is completed within 3 to 4 weeks; results are reviewed by a multidisciplinary team including Consultant Medical Genetics before release. You will receive a telephonic counselling session to discuss your results and their clinical implications.
3. What should I expect if my GSN test result is positive?
A positive result indicates that you carry a pathogenic GSN mutation, which increases your lifetime risk for developing Meretoja disease but does not guarantee symptom onset. Penetrance is high but age-dependent and variable. Following result disclosure, you will receive a telephonic post-test counselling session and a referral to neurology and clinical genetics for long-term surveillance, symptomatic management, and cascade testing of at-risk family members.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection
DNA Labs UAE operates under DHA Facility License Number 1143 and adheres to the highest standards of clinical governance and patient data protection. All genetic testing and associated data handling comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures follow the provisions of Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genetic data is encrypted, access-controlled, and never shared with third parties without your explicit written consent.
Clinical & Logistical Metadata
| Test Name | GSN Gene Finnish Type Amyloidosis Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA tube), extracted DNA, or dried blood spot on FTA card |
| Methodology Used | Next-Generation Sequencing (NGS) with full gene coverage and variant interpretation per ACMG guidelines |
| ICD-10-CM Code | E85.2 |
| LOINC Code | 94219-7 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians